The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 375.00
Bid: 360.00
Ask: 374.00
Change: 11.00 (3.02%)
Spread: 14.00 (3.889%)
Open: 375.00
High: 375.00
Low: 375.00
Prev. Close: 364.00
WIL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement and Q1 Trading Update

1 Nov 2018 07:00

RNS Number : 9329F
Wilmington PLC
01 November 2018
 

1 November 2018 

 

Wilmington plc

('Wilmington', 'the Group' or 'the Company')

AGM Statement and Q1 Trading Update

 

Wilmington plc, the provider of information, education and networking services in Risk & Compliance, Healthcare and Professional knowledge areas, today announces a trading update for the three month period to 30 September 2018. This statement is being made ahead of its Annual General Meeting that is taking place later today.

 

Trading Update

 

In what is traditionally the quietest trading period for the Group, revenue performance in the first quarter has been reasonable, with a mix of performances across the different divisions. Overall revenue reduced 1% on an organic basis (i.e. at constant currencies and after adjusting for acquisitions and disposals) compared to the same period last year. This compares to the 3% organic revenue decline experienced across the prior year.

 

On a divisional basis, revenue in the Risk & Compliance division was up 7% organically, with good momentum in the main Compliance business, partly as a result of favourable timing issues that accelerated revenue from Q2 into the first three months this year. In the Healthcare division revenue declined 7% on an organic basis reflecting the reduction in deferred revenue noted in September's full year results announcement, as well as the continued impact of the decision to reduce US networking events to focus on improving profitability. Importantly from the perspective of future revenue progression in Healthcare, new business sales in the first quarter in the UK Healthcare business were up over 2% year on year and early indications for Q2 are that sales are expected to be further up compared to weak comparatives in the prior year. Revenue in the Professional businesses was flat year on year, excluding the impact of Ark, the legal services business that was closed in the first half of last year. 

 

Profit in the period, as anticipated, was down year on year due to the previously disclosed cost increases and investments made last year. This position was exacerbated slightly by a weaker than expected product mix in Q1 although this is expected to be a timing issue that will reverse over the course of the full year.

 

Net debt at 30 September 2018 was £44.4m (30 June 2018: £39.6m; 30 September 2017: £42.4m). The outflow since the start of the year is a function of usual seasonal outflows, and the final earn-out payment for SWAT which was acquired in July 2016.

 

Outlook

 

There is no change in anticipated trading outlook since the full year 2018 results announcement on 12 September 2018. The overall outcome from the divisional revenue and sales performance in the first quarter gives some early encouragement that momentum across the Group is starting to shift as required to achieve full year revenue and profit expectations. Whilst uncertainties remain within the macro economic environment, the changes in regulations that will come into force in the UK as a result of Brexit are likely to lead to new business opportunities in the second half of the year which will help to underpin our growth plans.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

For further information, please contact:

Wilmington plc

Pedro Ros, Chief Executive Officer

Richard Amos, Chief Financial Officer

 

FTI Consulting

Charles Palmer / Dwight Burden / Leah Dudley

020 7422 6800

 

 

 

020 3727 1000

 

 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Healthcare and Professional areas. Wilmington employs close to 1,000 people and has customers in 120 countries. Wilmington plc is a premium listed company on the main market of the London Stock Exchange.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKEFDLLPFFF
Date   Source Headline
1st Nov 20182:07 pmRNSResult of AGM
1st Nov 20187:00 amRNSAGM Statement and Q1 Trading Update
1st Nov 20187:00 amRNSTotal Voting Rights
17th Oct 20185:13 pmRNSHolding(s) in Company
1st Oct 20185:44 pmRNSDirector/PDMR Shareholding
1st Oct 201810:18 amRNSTotal Voting Rights
25th Sep 201812:29 pmRNSHolding(s) in Company
21st Sep 20183:13 pmRNSDirector/PDMR Shareholding
20th Sep 20183:19 pmRNSDirector/PDMR Shareholding
19th Sep 20182:12 pmRNSShare Awards
12th Sep 20187:00 amRNSFinancial results for the year ended 30 June 2018
3rd Sep 20189:00 amRNSTotal Voting Rights
28th Aug 201810:39 amRNSHolding(s) in Company
1st Aug 20189:00 amRNSTotal Voting Rights
19th Jul 20187:00 amRNSSale of ICP Credit Reporting Business
10th Jul 20184:24 pmRNSHolding(s) in Company
10th Jul 20184:19 pmRNSHolding(s) in Company
9th Jul 20182:23 pmRNSHolding(s) in Company
6th Jul 20187:00 amRNSTrading Statement
2nd Jul 201810:29 amRNSVoting Rights and Capital
1st Jun 20189:00 amRNSTotal Voting Rights
9th May 20187:00 amRNSCapital Markets Day
1st May 20187:00 amRNSTotal Voting Rights
3rd Apr 20187:00 amRNSVoting Rights and Capital
19th Mar 20184:18 pmRNSBoard Change - Correction
19th Mar 201811:34 amRNSHolding(s) in Company
16th Mar 20181:06 pmRNSBoard Change
15th Mar 20183:36 pmRNSHolding(s) in Company
2nd Mar 20182:13 pmRNSDirector/PDMR Shareholding
1st Mar 20189:00 amRNSVoting Rights and Capital
26th Feb 20188:34 amRNSDirector/PDMR Shareholding
22nd Feb 20183:49 pmRNSHolding(s) in Company
22nd Feb 20187:00 amRNSInterim Results
22nd Feb 20187:00 amRNSAppointment of Martin Morgan as Chairman
14th Feb 20182:50 pmRNSHolding(s) in Company
1st Feb 20189:10 amRNSHolding(s) in Company
1st Feb 20189:00 amRNSVoting Rights and Capital
4th Jan 20187:00 amRNSAcquisition of Interactive Medica
2nd Jan 20189:00 amRNSVoting Rights and Capital
18th Dec 20174:43 pmRNSNotification of Interim Results
1st Dec 20177:00 amRNSVoting Rights and Capital
29th Nov 20177:00 amRNSAppointment of new Chief Financial Officer
23rd Nov 201710:34 amRNSDirector/PDMR Shareholding
2nd Nov 20172:43 pmRNSResult of AGM
2nd Nov 20177:00 amRNSAGM and Q1 Trading Update
1st Nov 20179:12 amRNSVoting Rights and Capital
6th Oct 20175:58 pmRNSHolding(s) in Company
5th Oct 20173:45 pmRNSHolding(s) in Company
5th Oct 20173:44 pmRNSHolding(s) in Company
2nd Oct 20172:49 pmRNSVoting Rights and Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.